Prevalence of multi-drug resistance and its risk factors among tuberculosis patients in Kaski, Nepal

D. Yadav, D. Yadav, R. Yadav
{"title":"Prevalence of multi-drug resistance and its risk factors among tuberculosis patients in Kaski, Nepal","authors":"D. Yadav, D. Yadav, R. Yadav","doi":"10.3126/SAARCTB.V16I2.23336","DOIUrl":null,"url":null,"abstract":"Introduction: Multidrug-resistant tuberculosis is an intense and feared problem, difficult to control and has shown a trend of increase worldwide. MDR-TB poses a therapeutic and infection control challenge with significantly higher rates of morbidity and mortality. Hence, this study was conducted with objective to assess prevalence of multidrug resistance and its risk factors among Tuberculosis patients in Kaski district. \nMethods: The main component of the study comprised institutional based cross sectional study design which was conducted in directly observed treatment short course (DOTS) centers in Kaski district. The study period was from July 2016 to December 2016. The sample size for the study was 175 participants. Data collection was done through interview with used interview schedule, and review of patient treatment cards. Data were entered in Epidata software and analyzed by using SPSS 20 version software. \nResults: The prevalence of multidrug resistance in Kaski district was 5.7 per cent. Variables such as TB history in past, TB treatment in past, and cured in past are found statistically significant (p<0.005). People with prior history of TB were shown to be 19 times more likely to get MDR TB than those with no prior history (OR=19.056, CI: 4.522-80.294). People with complete TB treatment in past were 0.2 times less likely to get MDR TB than those with incomplete TB treatment in past (OR=0.182, CI: 0.075-0.441). \nConclusion: Present of previous TB infection and prior treatment outcome (to be defaulted or failed in treatment) were also identified as the risk factors for developing MDR TB. Proper surveillance system is to be established in terms of complete treatment to all TB patients that leads the prevention from MDRTB and prevent potent expensive costs from medical care for MDRTB patients.","PeriodicalId":175434,"journal":{"name":"SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS","volume":"60 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3126/SAARCTB.V16I2.23336","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Multidrug-resistant tuberculosis is an intense and feared problem, difficult to control and has shown a trend of increase worldwide. MDR-TB poses a therapeutic and infection control challenge with significantly higher rates of morbidity and mortality. Hence, this study was conducted with objective to assess prevalence of multidrug resistance and its risk factors among Tuberculosis patients in Kaski district. Methods: The main component of the study comprised institutional based cross sectional study design which was conducted in directly observed treatment short course (DOTS) centers in Kaski district. The study period was from July 2016 to December 2016. The sample size for the study was 175 participants. Data collection was done through interview with used interview schedule, and review of patient treatment cards. Data were entered in Epidata software and analyzed by using SPSS 20 version software. Results: The prevalence of multidrug resistance in Kaski district was 5.7 per cent. Variables such as TB history in past, TB treatment in past, and cured in past are found statistically significant (p<0.005). People with prior history of TB were shown to be 19 times more likely to get MDR TB than those with no prior history (OR=19.056, CI: 4.522-80.294). People with complete TB treatment in past were 0.2 times less likely to get MDR TB than those with incomplete TB treatment in past (OR=0.182, CI: 0.075-0.441). Conclusion: Present of previous TB infection and prior treatment outcome (to be defaulted or failed in treatment) were also identified as the risk factors for developing MDR TB. Proper surveillance system is to be established in terms of complete treatment to all TB patients that leads the prevention from MDRTB and prevent potent expensive costs from medical care for MDRTB patients.
尼泊尔卡斯基肺结核患者多药耐药流行情况及其危险因素
导言:耐多药结核病是一个严重和可怕的问题,难以控制,并在世界范围内呈上升趋势。耐多药结核病对治疗和感染控制构成挑战,其发病率和死亡率明显较高。因此,本研究旨在评估Kaski地区结核病患者多药耐药情况及其危险因素。方法:本研究的主要组成部分是基于机构的横断面研究设计,在Kaski地区直接观察短程短程治疗中心进行。研究时间为2016年7月至2016年12月。该研究的样本量为175名参与者。通过使用访谈时间表进行访谈,并查看患者治疗卡来收集数据。数据用Epidata软件录入,用SPSS 20版软件分析。结果:Kaski区多药耐药率为5.7%,既往结核史、既往结核治疗、既往治愈等变量差异均有统计学意义(p<0.005)。有结核病史的人患耐多药结核病的可能性是没有结核病史的人的19倍(OR=19.056, CI: 4.522-80.294)。与过去接受过完全结核病治疗的人相比,过去接受过完全结核病治疗的人患耐多药结核病的可能性低0.2倍(OR=0.182, CI: 0.075-0.441)。结论:既往结核感染和既往治疗结果(未治疗或治疗失败)也被确定为发生耐多药结核病的危险因素。在对所有结核病患者进行全面治疗方面,应建立适当的监测系统,从而预防耐多药结核病,并防止耐多药结核病患者的医疗保健费用过高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信